Health Canada is informing Canadians that Apotex Incorporated is conducting a voluntary recall of one lot of Apo-Ramipril 5 mg capsules used to treat hypertension (high blood pressure). The recall of Lot JR2178 was made to retail outlets across Canada.
Medication in the affected lot being recalled has been found to contain intact but empty capsules – meaning that patients taking them may not receive the dose of medication needed to treat their medical condition.
Without appropriate treatment, hypertension may lead to heart attack, stroke, kidney problems, internal bleeding and improper blood circulation. Although Apo-Ramipril is authorized for treatment of hypertension, the ingredient in this medication may also be prescribed for patients who have recently had a heart attack, or who are at high risk of heart attack or stroke.
Canadians who have purchased the affected lot of Apo-Ramipril 5 mg capsules. Affected products bear the drug identification number (DIN 02251574) and are from Lot JR2178.
The company became aware of the issue when a customer complained. It found the same problem in some sample products retained by the manufacturer. Apotex initiated the recall of Lot JR2178 to retail outlets. Since the capsules of Apo-Ramipril 5
mg are not transparent, it may be difficult to determine whether a capsule from the affected lot is empty.
Health Canada is monitoring the voluntary recall of the product and informing Canadians of the risk. Should Health Canada become aware that this product remains available for sale in Canada, the Department will take appropriate action.
To report suspected adverse reaction to these or other health products, please contact the Canada Vigilance Program of Health Canada toll-free at 1-866-234-2345, or complete a
Canada Vigilance Reporting Form and send to us using one of these methods:
Consumers and health professionals wanting more information about this advisory from Health Canada can contact the Public Enquiries Line at 613-957-2991, or can call toll free at 1-866-225-0709.
Media enquiries related to this Advisory should be directed to Health Canada Media Relations at 613-957-2983.
Health Canada
613-957-2983
613-957-2991
1-866-225-0709